NCT00334750

Brief Summary

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
410

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2007

Geographic Reach
1 country

21 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2006

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 8, 2006

Completed
1.4 years until next milestone

Study Start

First participant enrolled

November 1, 2007

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2009

Completed
Last Updated

February 2, 2021

Status Verified

September 1, 2010

Enrollment Period

1.4 years

First QC Date

June 5, 2006

Last Update Submit

February 1, 2021

Conditions

Glaucoma, Open-AngleOcular Hypertension

Keywords

Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian

Outcome Measures

Primary Outcomes (1)

  • To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.

    duration of study

Secondary Outcomes (1)

  • To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.

    duration of study

Study Arms (1)

There is no intervention in this study

This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

Other: There is no intervention in this study.

Interventions

There is no intervention in this study.OTHER

This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

There is no intervention in this study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Canadian population

You may qualify if:

  • Subjects diagnosed at study visit or within 3 months of visit with OH
  • OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

You may not qualify if:

  • No prior treatment for OH or OAG
  • No prior ocular surgery or history of ocular trauma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Pfizer Investigational Site

Calgary, Alberta, T3E 7M8, Canada

Location

Pfizer Investigational Site

Edmonton, Alberta, T5H 0X5, Canada

Location

Pfizer Investigational Site

Edmonton, Alberta, T5H 3V9, Canada

Location

Pfizer Investigational Site

Nanaimo, British Columbia, V9R 5B6, Canada

Location

Pfizer Investigational Site

Vancouver, British Columbia, V6K 1V7, Canada

Location

Pfizer Investigational Site

Williams Lake, British Columbia, V2G 1H1, Canada

Location

Pfizer Investigational Site

Winnipeg, Manitoba, R3C 0N2, Canada

Location

Pfizer Investigational Site

Sydney, Nova Scotia, B1P 1P2, Canada

Location

Pfizer Investigational Site

Brampton, Ontario, L6V 1B4, Canada

Location

Pfizer Investigational Site

Hamilton, Ontario, L8M 1L6, Canada

Location

Pfizer Investigational Site

London, Ontario, N6A 4V2, Canada

Location

Pfizer Investigational Site

Mississauga, Ontario, L5L 1W8, Canada

Location

Pfizer Investigational Site

Oakville, Ontario, L6H 3P1, Canada

Location

Pfizer Investigational Site

Oakville, Ontario, L6L 5G8, Canada

Location

Pfizer Investigational Site

Toronto, Ontario, M4N 3M5, Canada

Location

Pfizer Investigational Site

Toronto, Ontario, M5M 1B2, Canada

Location

Pfizer Investigational Site

Toronto, Ontario, M5T 2S8, Canada

Location

Pfizer Investigational Site

Montreal, Quebec, H1T 2M4, Canada

Location

Pfizer Investigational Site

Montreal, Quebec, H1V 1G5, Canada

Location

Pfizer Investigational Site

Sherbrooke, Quebec, J1K 1EB, Canada

Location

Pfizer Investigational Site

Saskatoon, Saskatchewan, S7K 3H3, Canada

Location

Related Links

MeSH Terms

Conditions

Glaucoma, Open-AngleOcular HypertensionGlaucoma

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2006

First Posted

June 8, 2006

Study Start

November 1, 2007

Primary Completion

April 1, 2009

Study Completion

April 1, 2009

Last Updated

February 2, 2021

Record last verified: 2010-09

Locations

CA(21)